NSCLC patients who use tyrosine kinase inhibitors for an extended period may have an increased generation of lactate by their tumor cells, which stimulates TME cells to produce more hepatocyte growth factor (HGF), further increasing cancer resistance and development. The gene discussed is HGF; the disease is cancer.